Skip to main content
. 2002 Jan 15;109(2):261–267. doi: 10.1172/JCI13720

Figure 3.

Figure 3

Anti-CD40L treatment prevents induction of diabetes by oral OVA in RIP-OVAlo mice. RIP-OVAlo mice bearing OT-I and OT-II cells were injected intraperitoneally with 250 μg control mAb 6C8 (squares) or anti-CD40L mAb MR1 (circles). To mimic low-dose oral tolerance regimens, mice were then fed 0.5 mg OVA on five alternating days. Blood glucose was measured 12 days after the start of feeding; values above 12 mmol/l were considered diagnostic of diabetes. Data on individual mice are pooled from two experiments.